FDA Weighs Patients' Risk Tolerance in Approving Obesity Device
This article was originally published in The Gray Sheet
The agency approved EnteroMedics’ Maestro neuromodulator to treat obesity despite the device not meeting endpoints in its pivotal trial. The agency relied in part on a survey that found obese patients willing to take more risks in exchange for weight loss.
Register for our free email digests: